{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2018-01-24&answer.answeringMemberPrinted=Steve+Brine", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.dateOfAnswer=2018-01-24&answer.answeringMemberPrinted=Steve+Brine", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2018-01-24&_metadata=all&answer.answeringMemberPrinted=Steve+Brine", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answer.dateOfAnswer=2018-01-24&answer.answeringMemberPrinted=Steve+Brine", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2018-01-24&answer.answeringMemberPrinted=Steve+Brine", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.dateOfAnswer=2018-01-24&answer.answeringMemberPrinted=Steve+Brine", "items" : [{"_about" : "http://data.parliament.uk/resources/823372", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823372/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) has published a number of technology appraisal guidance documents on the treatment of ovarian cancer. NICE technology appraisal guidance makes recommendations for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of resources. NHS commissioners are legally required to fund drugs and treatments recommended through the technology appraisal programme within three months.<\/p><p> <\/p><p>NICE has positively appraised guidance on use of \u201cPaclitaxel in the treatment of ovarian cancer\u201d (TA:55), published in May 2005; \u201cOlaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy\u201d (TA:381), published in January 2016; and, \u201cTopotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer\u201d (TA:389), published in April 2016.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T12:11:27.223Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Ovarian Cancer: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the timetable is for the introduction of new medicines to help prevent the spread of ovarian cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "122855"}
    , {"_about" : "http://data.parliament.uk/resources/823373", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823373/answer", "answerText" : {"_value" : "<p>The appropriate use of prescribed medication for diabetes, and any actions to support this, can form part of the annual reviews between general practitioners and their diabetes patients. NHS England is also overseeing the investment of diabetes transformation funding towards improved access to diabetes structured education within individual clinical commissioning groups.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T12:02:40.28Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Diabetes: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with GPs and clinical bodies on improving the rate at which diabetics take their medications.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "122856"}
    , {"_about" : "http://data.parliament.uk/resources/823445", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823445/answer", "answerText" : {"_value" : "<p>Flu vaccines for people aged 18 years and older are procured directly from manufacturers and suppliers by providers. The procurement and distribution of flu vaccines for the children\u2019s aspect of the national flu programme is managed by Public Health England.<\/p><p> <\/p><p>Flu vaccine remains available to order from manufacturers and suppliers across England for both the adult and the children\u2019s aspects of the national flu immunisation programme.<\/p><p> <\/p><p>Officials are continuously monitoring the flu vaccine supply landscape to enable timely and appropriate action to be taken in the event that demand begins to outweigh the amount of flu vaccine that is currently available to patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "122924"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T11:59:58.84Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Influenza: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the availability of stocks of flu vaccines in (a) York and (b) England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
      }
      , "tablingMemberConstituency" : {"_value" : "York Outer"}
      , "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
      ], "uin" : "122923"}
    , {"_about" : "http://data.parliament.uk/resources/823446", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823446/answer", "answerText" : {"_value" : "<p>Flu vaccines for people aged 18 years and older are procured directly from manufacturers and suppliers by providers. The procurement and distribution of flu vaccines for the children\u2019s aspect of the national flu programme is managed by Public Health England.<\/p><p> <\/p><p>Flu vaccine remains available to order from manufacturers and suppliers across England for both the adult and the children\u2019s aspects of the national flu immunisation programme.<\/p><p> <\/p><p>Officials are continuously monitoring the flu vaccine supply landscape to enable timely and appropriate action to be taken in the event that demand begins to outweigh the amount of flu vaccine that is currently available to patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "122923"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T11:59:58.887Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Influenza: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans his Department has to increase the supply of flu vaccines to areas in the event that there are shortfalls of such vaccines during Winter 2017-18.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
      }
      , "tablingMemberConstituency" : {"_value" : "York Outer"}
      , "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
      ], "uin" : "122924"}
    , {"_about" : "http://data.parliament.uk/resources/823518", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823518/answer", "answerText" : {"_value" : "<p>Comparisons of uptake of medicines between different countries with different health systems are difficult and should be treated with caution. However, we are committed to working with industry on this issue and share the ambition to maximise the appropriate use of innovation in our system and tackle unwarranted variation in uptake. The Government and industry are currently working together through a series of workshops that will provide the foundation for the next medicines pricing scheme, and discussions around uptake, adoption and metrics have been a feature of those early meetings.<\/p><p> <\/p><p>The recent Government and partner bodies response to the Accelerated Access Review sets out how we will work with industry and the health system to create a streamlined and sophisticated approvals system so that cost-effective breakthrough products \u2013 be they drugs, devices, digital or diagnostics \u2013 can get into the National Health Service as fast as possible.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T11:57:48.51Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Life Sciences"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps are being taken to ensure that the UK enters the top quartile of comparator countries for the speed of adoption and overall uptake of innovative treatments as recommended in the Life Sciences Industrial Strategy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/104", "label" : {"_value" : "Biography information for Crispin Blunt"}
      }
      , "tablingMemberConstituency" : {"_value" : "Reigate"}
      , "tablingMemberPrinted" : [{"_value" : "Crispin Blunt"}
      ], "uin" : "122988"}
    , {"_about" : "http://data.parliament.uk/resources/823522", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823522/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is committed to playing its part in delivering the vision set out in the Life Sciences Industrial Strategy. Ensuring that appraisals are fit for purpose in a fast-changing sector is critical. NICE has recently taken steps to do this by introducing changes to its processes to support faster access to the most effective treatments, while addressing affordability issues. In addition, NICE has recently consulted on further changes to streamline its technology appraisal processes so that it is better able to develop new guidance on innovative drugs and medical technologies.<\/p><p> <\/p><p>As set out in the response to the Accelerated Access Review, we are also introducing a new Accelerated Access Pathway, to streamline regulatory and market access decisions for a small number of products, getting breakthrough products that we believe will be truly transformative to patients even more quickly.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T16:38:26.52Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Life Sciences"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps are being taken to update and evolve value assessments of drugs, medical devices and diagnostics, as recommended in the Life Sciences Industrial Strategy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/104", "label" : {"_value" : "Biography information for Crispin Blunt"}
      }
      , "tablingMemberConstituency" : {"_value" : "Reigate"}
      , "tablingMemberPrinted" : [{"_value" : "Crispin Blunt"}
      ], "uin" : "122991"}
    , {"_about" : "http://data.parliament.uk/resources/823523", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823523/answer", "answerText" : {"_value" : "<p>The Department wants patients with cystic fibrosis to benefit from clinically and cost effective treatments, and we welcome the on-going dialogue between Vertex and NHS England to pursue a deal that would make Orkambi available to National Health Service patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T12:13:27.687Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Lumacaftor/ivacaftor"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the extension of Orkambi's licence to treat patients aged six and over, what support his Department is giving to further negotiations among NICE, NHS England and the drug manufacturer, Vertex, on access to that medicine for people with cystic fibrosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/104", "label" : {"_value" : "Biography information for Crispin Blunt"}
      }
      , "tablingMemberConstituency" : {"_value" : "Reigate"}
      , "tablingMemberPrinted" : [{"_value" : "Crispin Blunt"}
      ], "uin" : "122992"}
    , {"_about" : "http://data.parliament.uk/resources/823588", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823588/answer", "answerText" : {"_value" : "<p>The Department has made no such estimate. FP10 prescriptions forms do not specify what clinical indication the medicine/device is being prescribed for, therefore the requested data is not collected.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T12:15:06.33Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an estimate of the average yearly cost to patients of paying for prescribed asthma medication.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/432", "label" : {"_value" : "Biography information for Helen Jones"}
      }
      , "tablingMemberConstituency" : {"_value" : "Warrington North"}
      , "tablingMemberPrinted" : [{"_value" : "Helen Jones"}
      ], "uin" : "123051"}
    , {"_about" : "http://data.parliament.uk/resources/823664", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823664/answer", "answerText" : {"_value" : "<p>The Department is aware of the intermittent issues affecting the supply of Pneumococcal polysaccharide 23-valent vaccine (PPV 23 vaccine). We are working closely with Public Health England (PHE) and the supplier, MSD, on this issue and can confirm that further United Kingdom deliveries are expected to be made available over the coming months. Despite this, supplies are expected to be constrained for the foreseeable future. In order to mitigate the impact to patients, PHE has issued clinical guidance to general practitioners, which provides recommendations on how to manage patients who are eligible for vaccination during periods of constraint.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T12:04:59.237Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pneumococcal Diseases: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure adequate supplies of the PPV23 vaccine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4649", "label" : {"_value" : "Biography information for Thelma Walker"}
      }
      , "tablingMemberConstituency" : {"_value" : "Colne Valley"}
      , "tablingMemberPrinted" : [{"_value" : "Thelma Walker"}
      ], "uin" : "123119"}
    , {"_about" : "http://data.parliament.uk/resources/823739", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/823739/answer", "answerText" : {"_value" : "<p>Patients with Huntington's disease have access to a range of services including the services of their general practitioner, associated health professionals neurology services, occupational therapy, speech and language therapy, local mental health services for sufferers and their families, palliative care where appropriate and online resources, including factsheets.<\/p><p> <\/p><p>A new drug for treatment of Huntington\u2019s disease was recently trialed in humans for the first time, in groundbreaking research supported by the Department\u2019s National Institute for Health Research (NIHR). Early results suggest that the new drug, known as IONIS-HTTRx, can successfully silence the faulty gene, lowering levels of the harmful huntingtin protein in the nervous system and slowing progression of the illness. The study was supported by the NIHR University College London Hospitals (UCLH) Biomedical Research Centre, the NIHR UCLH Clinical Research Facility and the NIHR Clinical Research Network. The research team now intends to move quickly to a larger trial to further confirm their findings.<\/p><p> <\/p><p>The Accelerated Access Review (AAR) was launched to make recommendations to the Government on speeding up access for National Health Service patients to innovative and cost-effective new medicines, diagnostics, medical technologies and digital products. On 3 November 2017, the Government published its response to the AAR. The response sets out how the Government will work with industry and healthcare organisations to implement the recommendations made by the review. The response is available online at:<\/p><p> <\/p><p><a href=\"https://www.gov.uk/government/publications/accelerated-access-review-response\" target=\"_blank\">https://www.gov.uk/government/publications/accelerated-access-review-response<\/a><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-01-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-01-24T16:40:01.893Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-01-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Huntington's Disease: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps the Government is taking to ensure people with Huntington's disease have appropriate access to emerging treatment methods.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3939", "label" : {"_value" : "Biography information for Andrew Percy"}
      }
      , "tablingMemberConstituency" : {"_value" : "Brigg and Goole"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Percy"}
      ], "uin" : "123184"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answer.dateOfAnswer=2018-01-24&answer.answeringMemberPrinted=Steve+Brine", "page" : 0, "startIndex" : 1, "totalResults" : 11, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}